Clinical trials: Sensory Neuropathy
Charcot-Marie-Tooth Neuropathy Type 1A, Hereditary Transthyretin Amyloid Neuropathy
Longitudinal Quantitative Neuromuscular MRI in Neuropathic Patients
The pathophysiological process common to neuropathies is fatty replacement of muscle tissue, more commonly known as intramuscular fat fraction (F.F).
- Conditions
- Charcot-Marie-Tooth Neuropathy Type 1A, Hereditary Transthyretin Amyloid Neuropathy, Acquired Demyelinating Neuropathy
- Trial name
- IMAGINERV (NCT06845644)
- Testing
- Quantitative neuromuscular MRI, Neuromuscular ultrasound
- Where
- France
- Volunteers
- 120 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Lower Extremity Amputee, Diabetic Peripheral Neuropathy
Functional and Neuroprotective Effects of Restoring Lower Limb Sensation After Diabetic Peripheral Neuropathy
The purpose of this study is to evaluate the effectiveness of providing sensation of the missing limb to individuals with above and below the knee limb loss.
- Trial name
- NCT04658693
- Testing
- Implanted Multi contact stimulating electrode and intramuscular electromyography recording electrode
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- VA Office of Research and Development
HER2-positive Breast Cancer
PIK3CA in HER2+ BC and pCR Trial
The goal of the study is to evaluate the impact of somatic PI3KCA mutations on pCR in HER2-positive early breast cancer in real life. The main question it aims to answer iS.
- Trial name
- NCT05750693
- Testing
- PIK3CA analysis
- Where
- Italy
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Rare Disorders, Undiagnosed Disorders
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
The Coordination of Rare Diseases at Sanford (CoRDS) is an international patient registry that serves as a centralized resource for rare disease research.
- Conditions
- Rare Disorders, Undiagnosed Disorders, Disorders of Unknown Prevalence, Cornelia De Lange Syndrome
- Trial name
- CoRDS (NCT01793168)
- Where
- United States
- Volunteers
- 20,000 people
- Sponsor
- Sanford Health
Overactive Bladder
ADRB3, ROCK2 and GEF Levels in Overactive Bladder Patients
Aims: To evaluate changes in levels of ADRB3, ROCK2, and GEF which have key roles in the adrenergic and cholinergic pathways of contraction-relaxation harmony in voiding physiology, and to investigate the diagnostic potential of…
- Trial name
- NCT04626960
- Where
- Turkey (Türkiye)
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Pamukkale University
Diabetic Peripheral Neuropathy
Adaptive Gamified Sensory Training on Sensory Function and Limb-Specific Functional Performance in Patients With Diabetic Peripheral Neuropathy
Diabetic peripheral neuropathy (DPN) will be considered a clinically important complication of diabetes mellitus that may impair sensory function and interfere with the performance of daily activities involving the hands and…
- Trial name
- NCT07907289
- Testing
- Adaptive Gamified Sensory Training, Conventional Physical Therapy Group
- Volunteers
- 40 people
- Sponsor
- Al-Zaytoonah University of Jordan
Diabetic Neuropathy
The Effect of Ruboxistaurin on Small Fiber Function
To determine the effect of Ruboxistaurin on small fiber function.
- Trial name
- NCT00190970
- Testing
- Ruboxistaurin
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Chromaderm, Inc.
Complex Regional Pain Syndrome I (CRPS I), Nerve Entrapment Syndrome
Median Nerve Decompression for Complex Regional Pain Syndrome: A Clinical Study
This clinical study evaluates the effectiveness of surgical treatment in patients with upper-limb complex regional pain syndrome (CRPS) diagnosed according to the Budapest criteria.
- Trial name
- CRPS-SURG (NCT07263256)
- Testing
- Lesion-Specific Surgical Correction, Median Nerve Decompression
- Where
- Czechia
- Volunteers
- 74 people
- Sponsor
- Jitka Fricova
Cognitive Impairment, Hereditary Spastic Paraplegia
Studying Cognition in SPG4
Comparing the cognitive levels of patients with SPG4 mutations to healthy controls.
- Trial name
- NCT03104088
- Testing
- CANTAB, MOCA
- Where
- Germany
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- University Hospital Tuebingen
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8
Acupuncture in Reducing Chemotherapy-Induced Peripheral Neuropathy in Participants With Stage I-III Breast Cancer
The goal of this study is to obtain preliminary evidence of the effect of 8 acupuncture treatments over 10 weeks in breast and GI cancer patients who are currently receiving or recently completed active neurotoxic chemotherapy…
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
- Trial name
- NCT03505671
- Testing
- Acupuncture Therapy, Best Practice, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Wake Forest University Health Sciences
Solid Tumor, Renal Cell Carcinoma (Kidney Cancer)
A Study of NDI 1150-101 in Patients With Solid Tumors
This study is to determine the maximum tolerated dose (MTD) and the recommended Phase 2 dose (RP2D) and to investigate the safety, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of NDI-101150 given as…
- Conditions
- Solid Tumor, Renal Cell Carcinoma (Kidney Cancer), Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma, Non-Small Cell Lung Cancer
- Trial name
- NCT05128487
- Testing
- NDI-101150, Pembrolizumab
- Where
- 19 sites in United States
- Volunteers
- 106 people
- Sponsor
- Nimbus Saturn, Inc.
Breast Cancer
Validation of Molecular Diagnostic Assays to Detect Cancer Biomarkers in Blood & Primary Tumor in ER+/HER2- MBC
Conventional biopsy and surgical tumor resection are invasive procedures that capture only one instance of the progression of the tumor. However, the genome of tumor is not static, but it is constantly altered during treatment.
- Trial name
- NCT04480814
- Testing
- PIK3CA kit
- Where
- 4 sites in Greece
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Pharmassist Ltd
Entrapment Neuropathy
Study Evaluating Treatment of Forefoot Pain Related to Nerve Entrapment Using the Cryo-Touch III Device
A proof of concept study to evaluate the feasibility of safe and effective treatment through optimization of the Cryo-Touch III Device for temporary relief of pain.
- Trial name
- NCT01753778
- Testing
- Cryo-Touch III Device
- Where
- 2 sites in United States
- Volunteers
- 7 people
- Sponsor
- Pacira Pharmaceuticals, Inc
Metastatic Breast Cancer
A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi
This study was a multicenter, randomized, double-blind, placebo-controlled Phase III study to determine the efficacy and safety of treatment with Buparlisib plus Fulvestrant vs.
- Trial name
- BELLE-3 (NCT01633060)
- Testing
- Fulvestrant, BKM120
- Where
- 197 sites in United States, Argentina and 20 more
- Volunteers
- 432 people
- Sponsor
- Novartis Pharmaceuticals
Colorectal Cancer, Advanced Gastric Cancer
A Study of the Efficacy and Safety of PerOx Quench on the Prevention of Oxaliplatin Treatment Induced Neuropathy
Chemotherapy-induced peripheral neuropathy (CIPN) is a progressive, enduring, and often irreversible condition featuring pain, numbness, tingling and sensitivity to cold in the hands and feet (sometimes progressing to the arms…
- Conditions
- Colorectal Cancer, Advanced Gastric Cancer, Neuropathy
- Trial name
- NCT02560740
- Testing
- PerOx Quench
- Where
- China
- Volunteers
- 9 people
- Sponsor
- SMR Biotech Co., Ltd.
Colorectal Cancer, Colon Cancer
CB-839 + Capecitabine in Solid Tumors and Fluoropyrimidine Resistant PIK3CA Mutant Colorectal Cancer
This study has two portions. The main goal of the Phase I portion of this research study is to see what doses of CB-839 and capecitabine can safely be given to patients without having too many side effects.
- Conditions
- Colorectal Cancer, Colon Cancer, Rectal Cancer, Solid Tumor
- Trial name
- NCT02861300
- Testing
- CB-839, Capecitabine
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- David Bajor, MD
Incurable Metastatic Colorectal Carcinoma, Incurable Progressive, Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Phase 1 and 2 Study of PX-866 and Cetuximab
The purpose of this Phase 1/2 open-label study is to determine the safety and efficacy of a cetuximab and PX-866 combination treatment.
- Trial name
- NCT01252628
- Testing
- PX-866 (SCCHN), Cetuximab (SCCHN), PX-866 (CRC)
- Where
- 40 sites in United States, Canada
- Volunteers
- 178 people
- Sponsor
- Cascadian Therapeutics Inc.
Healthy Volunteers
A Study to Determine the Relative Bioavailability of Capsule and Tablet Formulations of GDC-0941 and the Effect of Food and Proton Pump Inhibition on GDC-0941 Tablet Pharmacokinetics in Healthy Volunteers
This is a Phase I, randomized, two-part, single-center pharmacokinetics (PK) study to assess the relative bioavailability of capsule and tablet formulations of GDC-0941 in the fasted state (Part 1) and to determine the effect of…
- Trial name
- NCT00999128
- Testing
- GDC-0941, rabeprazole
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Genentech, Inc.
Haematologic Neoplasms
A Study of AZD2962, an IRAK4 Inhibitor (IRAK4 [a Body Protein] Blocker), in Participants With Haematologic Neoplasms (Blood Cancers)
The purpose of the study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of AZD2962, an Interleukin-1 Receptor-Associated Kinase 4 (IRAK4) inhibitor, as monotherapy and in…
- Trial name
- NCT07064122
- Testing
- AZD2962
- Where
- 21 sites in United States, Australia and 5 more
- Volunteers
- 72 people
- Sponsor
- AstraZeneca
CIPN - Chemotherapy-Induced Peripheral Neuropathy, Age Over 18
Sensory Rehabilitation in Chemo Induced Peripheral Neuropathy
This study is a cross-over RCT evaluating the effectiveness of 3 sessions a week apart of explicit sensory retraining to the lower extremities in individuals with CIPN versus usual care.
- Conditions
- CIPN - Chemotherapy-Induced Peripheral Neuropathy, Age Over 18, Chemotherapy-induced Peripheral Neuropathy
- Trial name
- NCT06724861
- Testing
- Explicit Sensory Retraining for the lower extremities, no treatment
- Where
- Israel
- Volunteers
- 27 people
- Sponsor
- Assaf-Harofeh Medical Center